In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Beijing SL Pharmaceutical Lamivudine Receives Approval

This article was originally published in PharmAsia News

Executive Summary

Beijing SL Pharmaceutical has received a production license and new drug certification for its lamivudine capsule and lamivudine raw material for treating the hepatitis B virus. At present, TIPR Pharmaceutical's Daiding ranks top in China's lamivudine market with 57.75 percent, and GSK's Heptodin accounting for the remaining market share. According to estimates, hospitals in the country spend RMB 480 million on lamivudine and the drug will hit RMB 1 billion in revenue by 2010. Beijing SL believes that few companies have the capability to produce the drug, and supply still lags behind demand. It is thus optimistic about the potential of the product and will go into production soon. (Click here for more - Chinese Language)
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC069489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel